Uric Acid as a Potential Mediator of Cardiovascular Morbidity in Obstructive Sleep Apnea Syndrome

CHEST Journal ◽  
2014 ◽  
Vol 145 (3) ◽  
pp. 607A
Author(s):  
Asiye Kanbay ◽  
Handan Inonu ◽  
Yalcin Solak ◽  
Abdulsamet Erden ◽  
Emine Uslu ◽  
...  
Keyword(s):  
Obstructive Sleep Apnea ◽  
Uric Acid ◽  
Sleep Apnea ◽  
Obstructive Sleep Apnea Syndrome ◽  
Sleep Apnea Syndrome ◽  
Cardiovascular Morbidity ◽  
Potential Mediator ◽  
Obstructive Sleep ◽  
Apnea Syndrome

scholarly journals MP003IS URIC ACID A MARKER IN OBSTRUCTIVE SLEEP APNEA SYNDROME?

2017 ◽  
Vol 32 (suppl_3) ◽  
pp. iii428-iii428
Author(s):  
Elif Torun Parmaksız ◽  
Ergün Parmaksız ◽  
Banu Salepçi ◽  
Gülten Güngör ◽  
Sevda Cömert ◽  
...  
Keyword(s):  
Obstructive Sleep Apnea ◽  
Uric Acid ◽  
Sleep Apnea ◽  
Obstructive Sleep Apnea Syndrome ◽  
Sleep Apnea Syndrome ◽  
Obstructive Sleep ◽  
Apnea Syndrome

scholarly journals Nuclear factor kappa B activation in cardiomyocytes by serum of children with obstructive sleep apnea syndrome

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Aviv D. Goldbart ◽  
Meital Gannot ◽  
Hen Haddad ◽  
Jacob Gopas
Keyword(s):  
Obstructive Sleep Apnea ◽  
Sleep Apnea ◽  
Obstructive Sleep Apnea Syndrome ◽  
Sleep Apnea Syndrome ◽  
Cardiovascular Morbidity ◽  
Positive Pressure ◽  
Rat Cardiomyocytes ◽  
Pressure Therapy ◽  
Obstructive Sleep ◽  
Apnea Syndrome

AbstractObstructive sleep apnea syndrome (OSA) is associated with cardiovascular morbidity in adults and children. NFκB activity is enhanced in circulating monocytes of adults with OSA, that decreases following positive pressure therapy. OSA children’s serum activates NFκB in a cell line. We hypothesized that OSA children’s serum can activate NFκB in cardiomyocytes (CM) and effect their viability. In order to explore the role played by NFκB in OSA cardiovascular pathophysiology, rat, mouse and human immortalized CM were exposed to human serum drawn from OSA children and matched controls. Increased expression of NFκB classical subunits p65/p50 as well as major morphological changes occurred in cardiomyocytes following OSA’s serum exposure. OSA children’s serum induced NFκB activity as measured by p65 nuclear translocation in immortalized human CM and rat cardiomyocytes as well as dense immunostaining of the nucleus. Trypan blue and XTT assays showed that OSA sera induced CM apoptosis. We conclude that NFκB is systemically activated in cardiomyocytes, who also demonstrate decreased viability and contractility following exposure to OSA serum. It supports the hypothesis NFκB plays a role in the evolution of cardiovascular morbidity in OSA. It may support the search for new therapeutic interventions controlling NFκB activation in OSA.

scholarly journals Cardiovascular Risk Assessment in a Cohort of Newly Diagnosed Patients with Obstructive Sleep Apnea Syndrome

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Kostas Archontogeorgis ◽  
Athanasios Voulgaris ◽  
Evangelia Nena ◽  
Maria Strempela ◽  
Panagiota Karailidou ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Obstructive Sleep Apnea ◽  
Sleep Apnea ◽  
Obstructive Sleep Apnea Syndrome ◽  
Sleep Apnea Syndrome ◽  
Cardiovascular Morbidity ◽  
Newly Diagnosed ◽  
Obstructive Sleep ◽  
Cardiovascular Morbidity And Mortality ◽  
Apnea Syndrome

Objectives. Obstructive sleep apnea syndrome (OSAS) is associated with increased cardiovascular morbidity and mortality. The aim of this study was to assess whether the 10-year risk for cardiovascular disease in newly diagnosed patients with OSAS is increased. Materials and Methods. Recently diagnosed, with polysomnography, consecutive OSAS patients were included. The Systematic Coronary Risk Evaluation (SCORE) and the Framingham Risk Score (FRS) were used to estimate the 10-year risk for cardiovascular disease. Results. Totally, 393 individuals (73.3% males), scheduled to undergo a polysomnographic study with symptoms indicative of OSAS, were enrolled. According to apnea-hypopnea index (AHI), subjects were divided in four groups: mild OSAS (AHI 5–14.9/h) was diagnosed in 91 patients (23.2%), moderate OSAS (AHI 15–29.9/h) in 58 patients (14.8%), severe OSAS (AHI > 30/h) in 167 patients (42.5%), while 77 individuals (19.6%) had an AHI < 5/h and served as controls. Increased severity of OSAS was associated with increased SCORE p<0.001 and FRS values p<0.001. More specifically, a significant correlation was observed both between AHI and SCORE r=0.251, p<0.001 and AHI and FRS values r=0.291, p<0.001. Furthermore, a negative correlation was observed between FRS values and sleep efficiency r=−0.224, p=0.006. Conclusions. The 10-year risk for cardiovascular morbidity and mortality seems to increase with severity of OSAS. Physicians should bear this finding in mind, in order to seek for and consecutively eliminate risk factors for cardiovascular disease and to prevent future cardiovascular events in OSAS patients.

Serum uric acid and arterial lactate levels in patients with obstructive sleep apnea syndrome: the effect of CPAP treatment

2021 ◽  
pp. 1-7
Author(s):  
Konstantinos Bartziokas ◽  
Andriana I. Papaioannou ◽  
Aikaterini Haniotou ◽  
Evangelia Nena ◽  
Konstantinos Kostikas ◽  
...  
Keyword(s):  
Obstructive Sleep Apnea ◽  
Uric Acid ◽  
Sleep Apnea ◽  
Obstructive Sleep Apnea Syndrome ◽  
Serum Uric Acid ◽  
Sleep Apnea Syndrome ◽  
Arterial Lactate ◽  
Obstructive Sleep ◽  
Apnea Syndrome ◽  
Lactate Levels
Sign in / Sign up

Export Citation Format

Share Document